223749-46-0 Usage
Description
(+)-N-[2,2-Dimethyl-3(R)-hydroxy-6-(4,4,4-trifluorobutoxy)-3,4-dihydro-2H-1-benzopyran-4(S)-yl]-N-methylmethanesulfonamide, also known as Niflumic acid, is a nonsteroidal anti-inflammatory drug with potent activity against a wide range of inflammatory and painful conditions. It works by inhibiting the synthesis of prostaglandins and leukotrienes, which are mediators of inflammation and pain.
Uses
Used in Pharmaceutical Industry:
Niflumic acid is used as an anti-inflammatory and analgesic agent for the treatment of various conditions such as arthritis, menstrual cramps, and injuries. Its effectiveness in managing pain, inflammation, and stiffness makes it a widely used medication in this industry.
Used in Oral Capsules and Tablets:
Niflumic acid is available in several forms, including oral capsules and tablets, making it a convenient and accessible option for patients seeking relief from inflammatory and painful conditions.
Used for Inflammation and Pain Management:
Niflumic acid is used for the management of various inflammatory and painful conditions due to its potent activity against prostaglandins and leukotrienes, which are key mediators of inflammation and pain.
Used for Patient Relief:
As a medication that is generally well-tolerated with common side effects such as nausea, indigestion, and headache, Niflumic acid provides relief to patients suffering from a range of inflammatory and painful conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 223749-46-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,3,7,4 and 9 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 223749-46:
(8*2)+(7*2)+(6*3)+(5*7)+(4*4)+(3*9)+(2*4)+(1*6)=140
140 % 10 = 0
So 223749-46-0 is a valid CAS Registry Number.
223749-46-0Relevant articles and documents
Synthesis and activity of novel and selective Iks-channel blockers
Gerlach,Brendel,Lang,Paulus,Weidmann,Brüggemann,Busch,Suessbrich,Bleich,Greger
, p. 3831 - 3837 (2007/10/03)
Since the discovery of the IKs-potassium channel as the slowly activating component of the delayed rectifier current (Ik) in cardiac tissue, the search for blockers of this current has been intense. During the screening of KATP